[Consensus-recommendations for sirolimus in liver transplantation].
Sirolimus is an m-TOR inhibitor without renal side effects and potentially protects against the development of malignancy. Due to a higher incidence of complications in two trials and an official warning in the drug information, the use of Sirolimus in liver transplantation is limited. The participants of this consensus meeting had to analyse and evaluate the literature with respect to the potential role of Sirolimus in liver transplantation. This consensus statement follows the scheme normally employed for the presentation of guidelines including the grading of evidence (1a-5) and the extent of recommendation (A-C). Moreover, the consensus included the experience of the authors with respect to the handling of Sirolimus after liver transplantation.
Golling
M
M
Klinik für Allgemein- und Gefässchirurgie am Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt am Main.
Becker
T
T
Broelsch
C
C
Candinas
D
D
Faust
D
D
Fischer
L
L
Geissler
E
E
Graeb
C
C
Iberer
F
F
Klupp
J
J
Kraus
T
T
Müller
A R
AR
Neuhaus
P
P
Strassburg
C P
CP
Wolff
M
M
Zülke
C
C
Bechstein
W O
WO
D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D017410:Practice Guidelines as Topic; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus